Health Service Executive. (2021) Guidance on appropriate prescribing of benzodiazepines and z-drugs (BZRA) for the treatment of anxiety and insomnia. Dublin: Health Service Executive.
Preview | Title | Contact |
---|---|---|
|
PDF (Guidance on appropriate prescribing of benzodiazepines and z-drugs (BZRA))
- Published Version
1MB |
This document aims to support the appropriate prescribing of benzodiazepines and z-drugs (BZRA) in Ireland. It contains information on initiation and review of BZRA, highlighting the potential dangers associated with long-term use and provides examples of resource materials which may support prescribers and pharmacists to manage the withdrawal of patients from these medicines. This guidance includes the changes made by the Misuse of Drugs Regulations 2017 (including 2020 amendment) which have replaced the now revoked Misuse of Drugs Regulations 1988, as amended. It is anticipated that the adoption of this guidance by prescribers will lead to a reduction in the long term inappropriate prescribing of these medicines.
B Substances > New (novel) psychoactive substances > Benzodiazepines
B Substances > New (novel) psychoactive substances > Other novel substances > Zopiclone, eszopiclone, zaleplon and zolpidem
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
F Concepts in psychology > Emotion (anxiety / joy)
J Health care, prevention, harm reduction and treatment > Risk and protective factors > Risk factors
L Social psychology and related concepts > Legal availability or accessibility
N Communication, information and education > Recommendations > Practice / clinical guidelines
T Demographic characteristics > Doctor / physician
T Demographic characteristics > Nurse / Midwife
T Demographic characteristics > Pharmacist
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page